Introduction
Ipamorelin and GHRP-6 both stimulate growth hormone release by activating the ghrelin/GHS receptor on anterior pituitary somatotroph cells. However, ipamorelin is widely recognized as the most selective GH secretagogue available, producing GH release with minimal effects on cortisol, prolactin, and appetite. GHRP-6, by contrast, has broader hormonal activity that includes significant ghrelin-like appetite stimulation and cortisol elevation. These differences make each peptide suited to different research contexts.
Mechanism of Action Comparison
Ipamorelin is a pentapeptide that selectively activates GHS-R1a receptors on pituitary somatotrophs without significantly engaging other receptor subtypes. This selectivity means GH release occurs in a dose-dependent manner without proportional increases in ACTH, cortisol, or prolactin[1]. Ipamorelin also does not significantly stimulate appetite or gastric motility.
GHRP-6 activates the same GHS-R1a receptor but with less selectivity. It produces robust GH release accompanied by measurable increases in cortisol (~15-20% elevation), prolactin, and strong appetite stimulation through central ghrelin pathways. GHRP-6 also stimulates gastric acid secretion and motility, making it relevant for GI motility research but problematic for studies requiring hormonal isolation.
Key Differences
| Feature | Ipamorelin | GHRP-6 |
|---|---|---|
| Selectivity | Highest among GHRPs | Moderate — broad activity |
| GH Release Potency | Moderate-high | High |
| Cortisol Impact | Negligible | Significant elevation |
| Prolactin Impact | Negligible | Moderate elevation |
| Appetite Stimulation | Minimal | Strong (ghrelin-like) |
| Gastric Motility | No effect | Increased |
Research Applications
Ipamorelin is the preferred secretagogue for clean GH-axis studies where cortisol and prolactin confounding must be minimized. It pairs exceptionally well with CJC-1295 No DAC for synergistic pulsatile GH release. GHRP-6 is valuable in appetite and ghrelin-pathway research, gastric motility studies, and protocols where robust GH release is prioritized over hormonal selectivity. GHRP-6's appetite-stimulating properties also make it relevant for cachexia and wasting research.
Which to Choose for Your Research?
For most GH-axis research, ipamorelin's superior selectivity makes it the default choice, particularly in combination protocols. Choose GHRP-6 when appetite stimulation is a desired endpoint, when studying ghrelin receptor biology broadly, or when maximum GH amplitude is needed regardless of cortisol and prolactin co-elevation. For anti-aging or body composition research, ipamorelin's cleaner profile is preferred.
